A new monograph from German health regulators that defines cannabis extracts (Cannabis extractum normatum) might require companies currently selling or planning to peddle these products in Germany to adapt their formulations.

The new entry in the latest version of the German pharmacopoeia (Deutsches Arzneibuch, DAB) went into effect June 1.



<!–

var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || [];
var abkw = window.abkw || ”;
var plc299585 = window.plc299585 || 0;
document.write(”);
AdButler.ads.push({handler: function(opt){ AdButler.register(172085, 299585, [300,250], ‘placement_299585_’+opt.place, opt); }, opt: { place: plc299585++, keywords: abkw, domain: ‘servedbyadbutler.com’, click:’CLICK_MACRO_PLACEHOLDER’ }});
–>

var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || [];
var abkw = window.abkw || ”;
var plc299585 = window.plc299585 || 0;
document.write(”);
AdButler.ads.push({handler: function(opt){ AdButler.register(172085, 299585, [300,250], ‘placement_299585_’+opt.place, opt); }, opt: { place: plc299585++, keywords: abkw, domain: ‘servedbyadbutler.com’, click:’CLICK_MACRO_PLACEHOLDER’ }});

Before this document, full-spectrum cannabis extracts were considered legal in Germany, but neither the national nor the European pharmacopoeia defined them.

The German pharmacopoeia – binding only on a national level – has included a cannabis monograph since 2017 – but only for flower.

No European cannabis monograph exists, but a draft is in the works. If ever published, a European cannabis monograph would facilitate standardization across the continent.

To comply with the cannabis extracts rules, Canadian-based Tilray changed the carrier oil of the full-spectrum extract THC25, which it sells in Germany, Apotheke Ad-Hoc reported.

According to the report, Tilray THC25 oil started using medium-chain triglycerides (MCT) as carrier oil instead of grape seed oil, which the company had been using.

THC25 is a full-spectrum oil that has 25 milligrams/milliliters of THC and less than 0.5 milligrams/milliliters of CBD, sold in 25-milliliter bottles.

Pharmacists dispensing magistral preparations in Germany – the category under which Tilray oils are currently sold – must, among other things, test the products before handing them over to patients.

According to Apotheke Ad-Hoc, Tilray will continue providing the same THC “rapid test” as before because it also works with the new formulation, delivering the result in only a few minutes. This is much faster than a thin-layer chromatography (TLC).

In theory, pharmacists should conduct a TLC to test cannabis extracts, but several regional German health authorities tolerate simpler alternatives.

Sita Schubert, secretary general of the European Medicinal Cannabis Association, recently recommended lowering the minimum THC called for in the new German monograph for cannabis extracts from 1% to 0.2%.

The 1% THC lower limit in the monograph means that only products with at least that percentage of THC qualify as medicinal cannabis extracts.

According to the EUMCA, this could deny younger patients “access to their existing treatments,” and “the physician, not the policymaker … should be making the decision on the appropriate course of treatment and formulation for their patient.”

Alfredo Pascual can be reached at [email protected]

Pure CBD Hemp Oil

  • Pure CBD Tincture, derived from organic, US-harvested hemp, lab-tested for quality.

  • Clinically proven therapeutic effects.

  • Relieves anxiety and stress

  • Eliminates chronic pain and aches

  • Regulates mood and sleep patterns

  • Enhances focus and clarity

pure cannabis oil

George Scorsis website

Originally posted on via Cannabis Industry News

Author: George Scorsis

Mr. George Scorsis has more than 15 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks and, most recently, medical cannabis. Formerly CEO of Liberty Health Sciences, Mr. Scorsis leveraged his extensive background in managing growth within a highly regulated environment to expand Liberty Health Sciences Inc.’s cannabis-related platforms in the United States. Prior to joining Liberty Health Sciences, Mr. Scorsis was President of Red Bull Canada where he was instrumental in restructuring the organization from a geographical and operational perspective, growing the business to $150 MM in revenue. He also worked closely with Health Canada on guidelines regulating the energy drink category while also establishing a corporately owned distribution model in volatile markets. As the previous President at Mettrum Health Corp., a leading Canadian cannabis distributor, Mr. Scorsis contributed to the company becoming an industry leader and eventually seeing the organization sell for $ 430 MM. He also served as Chairman of the Board of Directors of Scythian Biosciences Corp., a research and development company committed to advancing treatment efforts for traumatic brain injury with its proprietary cannabinoid-based combination drug therapy and additional cannabis-related activities across the globe.

Design a site like this with WordPress.com
Get started